Co-Diagnostics and CoMira Unveil Automated Manufacturing Line in Utah
Co-Diagnostics hosted a delegation from CoMira Diagnostics, its joint venture in the Kingdom of Saudi Arabia, for the unveiling of a future automated manufacturing line at its Salt Lake City headquarters, announced in a press release. The event took place on June 17, 2026, and was attended by Utah state officials, trade representatives, and community leaders.
The visit marked the next phase of Co-Diagnostics' partnership with CoMira, which involves transferring molecular diagnostics technology and manufacturing capabilities to Saudi Arabia. The future automated PCR test kit manufacturing line is expected to support rapid scaling of diagnostic production and distribution across Saudi Arabia and 18 other countries in the Middle East and North Africa.
The Co-Dx PCR platform integrates artificial intelligence and cloud-connected outbreak surveillance features to enable real time monitoring of infectious disease trends. These capabilities are planned to be part of the CoMira partnership, aligning with the goal of establishing automated diagnostic infrastructure in international markets.
According to CoMira CEO Ihssan Rjoob, the visit provided insight into the advanced manufacturing systems that will form the foundation of CoMira’s operations in Saudi Arabia. Co-Diagnostics’ platform is designed to support scalable and efficient test production for regional healthcare needs.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Nov 13 ETR survey: Claude leads enterprise AI tools on satisfaction and spending plans Nov 13 Peter Sarlin's PostScriptum takes majority stake in Finnish AI deployment firm Brillian Nov 13 Gondola says Codex lifted engineering output 25% as revenue more than doubled Nov 13 DuPont teams with Microsoft and NobleAI to speed up R&D with AI Nov 13 Korean AI startups fear Huang exit could delay planned NVIDIA investmentsMore from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareIndustrial AI Weekly
The latest advancements in smart manufacturing, predictive maintenance, AI-driven quality control, supply chain & more.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Rika Sensor Supplies 86 Coolant Monitoring Units for Dubai AI Data Center
AstraZeneca and Oracle Partner on AI for Clinical Trials
Illumina Adds Three Research Tools to BioInsight Platform
Aramco Closes Deal for 49% HUMAIN Stake With $2.6 Billion Cash Contribution
BioMap Announces 11 AI Life Science Collaborations
Daily AI Brief: the AI news that matters, in your inbox.